LFCR: Lifecore Company Aggregate Debts

Symbol and logo of brand lifecore.com (LFCR)

Lifecore Biomedical (LFCR) provides comprehensive clinical trial support, helping to accelerate the launch of new drugs. The business relies on unique expertise in the mass production of complex viscous formulations, creating a foundation for global science. This chart on GURU.Markets reflects debt dynamics, which currently stand at -0.31. Meanwhile, the CDMO manufacturer is restoring stability following an audit, focusing on current orders without any new merger and acquisition deals.

Lifecore Biomedical Inc. - LFCR Company Debts (period 04/28/2023 - 10/27/2026)
Original product of Lifecore Biomedical, Inc.

The total amount of borrowed capital determines a business's degree of financial independence and its resilience to external shocks. Analyzing aggregate loans and credits allows for an assessment of the volume of attracted funds directed toward asset development. This metric measures the debt load affecting the company's net value. For Lifecore Biomedical (LFCR), this indicator is critical due to the costs associated with plant modernization. High liabilities in the CDMO sector increase risks in the event of losing key customers.